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Background: Rare hematopoietic stem cell populations are responsible for the transplantation engraftment
process. Umbilical cord blood (UCB) is usually processed to the total nucleated cell (TNC), but not to the
mononuclear cell (MNC) fraction. TNC counts are used to determine UCB unit storage, release for transplantation
and correlation with time to engraftment. However, the TNC fraction contains varying concentrations of red blood
cells, granulocytes, platelets and other cells that dilute and mask the stem cells from being detected. This does not
allow the quality and potency of the stem cells to be reliably measured.
Methods: 63 UCB segments and 10 UCB units plus segments were analyzed for the response of both primitive
lympho-hematopoietic and primitive hematopoietic stem cells in both the TNC and MNC fractions. The samples
were analyzed using a highly sensitive, standardized and validated adenosine triphosphate (ATP) bioluminescence
stem cell proliferation assay verified against the colony-forming unit (CFU) assay. Dye exclusion and metabolic
viability were also determined.
Results: Regardless of whether the cells were derived from a segment or unit, the TNC fraction always produced a
significantly lower and more variable stem cell response than that derived from the MNC fraction. Routine dye
exclusion cell viability did not correspond with metabolic viability and stem cell response. Paired UCB segments
produced highly variable results, and the UCB segment did not produce similar results to the unit.
Discussion: The TNC fraction underestimates the ability and capacity of the stem cells in both the UCB segment
and unit and therefore provides an erroneous interpretation of the of the results. Dye exclusion viability can result
in false positive values, when in fact the stem cells may be dead or incapable of proliferation. The difference in
response between the segment and unit calls into question the ability to use the segment as a representative
sample of the UCB unit. It is apparent that present UCB processing and testing methods are inadequate to properly
determine the quality and potency of the unit for release and use in a patient.
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Hematopoietic stem cell transplantation using bone
marrow, mobilized peripheral blood or umbilical cord
blood (UCB) as stem cell sources, are routine clinical
procedures. Yet the presence and functionality of the
stem cells is mostly assumed, rather than actually mea-
sured. The methylcellulose colony-forming unit (CFU)
assay has been used to detect many different cell popula-
tions from stem cells with high proliferative potential
[1-4] to precursor cells that demonstrate few cell divi-
sions [5,6]. Although the assay is not routinely used in
bone marrow or mobilized peripheral blood stem cell
transplantation processing [7], a functional assay is rou-
tinely required for cord blood processing, since UCB units
are cryopreserved and engraftment occurs later than that
for bone marrow or mobilized peripheral blood [8,9].
However, rather than detecting stem cells, the CFU assay
is usually employed to detect granulocyte-macrophage
(GM) progenitor cells as an indicator of time to neutrophil
engraftment [10]. With the exception of CD34 enumer-
ation, which became routine in the early 1990s [11], the
CFU assay together with total nucleated cell (TNC)
counts and viability represent the three basic tests that
have been continuously used to characterize UCB cells for
storage and transplantation purposes since the first UCB
transplant in 1988 [12].
Since its introduction in 1966 for murine cells [13,14],
and later for human bone marrow cells [15], counting col-
onies in a methylcellulose CFU assay has been the method
of choice to determine primitive hematopoietic cell func-
tionality. However, both clonal and liquid culture assays
have been reported using an instrument-based MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5,-diphenyltetrazolium brom-
ide) colorimetric readout, based on the reduction of the
tetrozolium substrate by the mitochondria to a yellow for-
mazan product. This provides a metabolic viability version
of the CFU assay [16-18]. The ability to use an instrument-
based, biochemical readout, such as MTT, laid the ground-
work for combining the methylcellulose clonal CFU assay
with an adenosine triphosphate (ATP) marker for measur-
ing in vitro hematopoietic stem and progenitor cell prolifer-
ation ability. This was demonstrated in 2005 [19], and later
used to evaluate umbilical cord blood progenitor cells [20].
Adenosine triphosphate is the cell’s source of chemical
energy. It is produced in the mitochondria of cells. He-
patocytes and kidney cells for example, have inherently
high levels of ATP associated with their high levels of
metabolism. Other cells, such as quiescent stem cells,
exhibit low levels of metabolism and therefore have low
basal levels of ATP production. Cells require ATP for
numerous biochemical reactions, from cellular respir-
ation to DNA synthesis and cell division. During these
reactions, ATP is reduced to adenosine di- (ADP) and
monophosphate (AMP) and the high-energy phosphateatoms are recycled to produce more ATP. It follows that
ATP is vital to the cell’s metabolism and health; cells that
do not or cannot produce ATP are metabolically dead.
Crouch et al. introduced the use of ATP biolumines-
cence measurement for proliferating cells in 1993 [21].
The reaction requires the addition of luciferin and the
enzyme luciferase to produce oxyluciferin, which creates
a bioluminescence signal that is measured as photons by
a luminometer. To measure intracellular ATP (iATP) in
cells, the ATP must be the limiting factor. The reaction
also requires the presence of oxygen. Red blood cells
(RBC), although they do not contain mitochondria, have
both high levels of ATP and oxygen. If ATP is being
used to measure cell proliferation in suspensions con-
taining high concentrations of RBCs, the latter acts as
an impurity in the cell preparation producing false posi-
tive results. Simply removing or reducing the RBCs can
negate the problem. However, if the RBCs are lysed, the
presence of hemoglobin can inhibit the ATP luciferin/lu-
ciferase reaction and cause low ATP concentrations. The
presence of RBCs could therefore pose a problem to
characterize rare stem cell populations in hematopoietic
cell therapy products that use a total nucleated cell (TNC)
fraction. This is because RBCs and other cell impurities,
including granulocytes, platelets and other cell types, can
be present in varying amounts depending on the process-
ing method [22].
Although it was shown that UCB units could be proc-
essed by density gradient centrifugation to produce large
numbers of mononuclear cells (MNCs) [23,24], the TNC
fraction is the product of choice. It is more rapidly pro-
duced than the MNC fraction and is less costly. Over the
years, the TNC and CFU counts, number of CD34+ cells
and even viability have all been associated, to varying de-
grees, with clinical outcome [10,25,26]. In addition, these
and especially TNC, are used as decision-making parame-
ters to permanently store UCB units for transplantation
purposes and select and release a unit for use in a patient.
One of the major hurdles in stem cell transplantation
has been the standardization, optimization and valid-
ation of procedures and assays [27,28] required to pro-
duce a stem cell product that can be accurately and
reliably characterized prior to use. Numerous articles
have addressed issues such as processing procedures,
cryopreservation techniques, pre-freeze and post-thaw
methodologies. Nevertheless, viability, CD34, the CFU
assay and clinical outcome are based on the TNC frac-
tion. Therefore, despite the problems associated with a
TNC fraction to detect and measure the presence of
stem cells, we tested a “null hypothesis” by assuming
that UCB segments and units did not have to be further
purified in order to reliably and reproducibly measure
stem cells in a standardized and validated assay. In short,
measurement of UCB stem cells should not be dependent
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sented below reject that hypothesis and call into question
UCB quality and potency based on the TNC fraction.
Materials and methods
Umbilical cord blood samples
Umbilical cord blood sample segments used in this study
were purchased from two different cord blood banks as
cryopreserved research samples. Cord blood bank (CBB)
1 processed samples using Sepax technology (BioSafe
America), while CBB 2 employed AXP technology (Cesca
Therapeutics, formerly ThermoGenesis, Rancho Cordova,
CA). In addition, individual units with attached segments
were also obtained. No pre-freeze samples were available
for these studies. Donors gave their consent for the cells
to be used for research purposes. The segment volume
ranged from 0.2 mL to less than 0.1 mL. The unit volumes
were between 20 mL to 30 mL each.
Preparation of samples for use
Umbilical cord blood segments and units were both
thawed in a 37°C water bath. After thawing a segment, a
1 mL syringe attached to a 22 gauge needle was used to
puncture two holes in the top of the segment and the
contents gently mixed before removing the cells. The
volume was noted and the contents transferred to a
2 mL tube containing the same volume of Iscove’s Modi-
fied Dulbecco’s Medium (IMDM, Life Technologies).
The contents were gently mixed, but a wash step was
not performed. This would be a normal procedure if
cells from a segment were tested, since the number of
cells available would be reduced by a wash step. How-
ever, for some of the segments, a small volume was re-
moved, without any additional treatment, to perform a
differential cell count (Medonic CA620, Stockholm,
Sweden), viability using 7-aminoactinomycin D (7-AAD)
by flow cytometry (Accuri C6, BD Biosciences) and
nucleated cell count (Z2 particle counter, Beckman
Coulter). This post-thaw, unseparated fraction was des-
ignated the TNC fraction. The remaining cells were
under-layered with 1.0 mL of NycoPrep 1.077 (Axis
Shield, Oslo, Norway) density gradient medium and cen-
trifuged according to the manufacturer’s instructions.
The interface cells were removed and transferred to an-
other tube. This separated cell fraction was designated
the MNC fraction, which was resuspended in 2.0 mL of
IMDM, centrifuged at 200 × g for 10 minutes at room
temperature to wash the cells. The resulting cell pellet
was resuspended in 0.2 mL of IMDM. A second nucle-
ated cell count, viability, and for some samples, a differ-
ential cell count was performed. Umbilical cord blood
units were handled and processed in exactly the same
manner, except that the contents of the units were
allowed to drain into a 50 mL tubed through one of theports, mixed gently and aliquoted into 0.3 mL samples
and transferred to 2 mL tubes for processing after sev-
eral samples had been removed to obtain initial differen-
tial and nucleated cell counts and viability values. Each
0.3 mL aliquot was diluted with 0.3 mL of IMDM and
fractionated using the same procedure as the segments.
Colony-Forming Unit (CFU) assay
A miniaturized CFU assay (CAMEO-4, HemoGenix,
Colorado Springs, CO) was performed as previously
described [29]. The cell concentration was adjusted to
0.5 × 106 cells/mL and a 3-point cell dose response pre-
pared to produce final concentrations. The total volume
prepared was 0.6 mL, including cells. Using a positive
displacement electronic pipette (Eppendorf, Hamburg,
Germany), 0.1 mL was dispensed into 4 replicate wells
in a 35 mm Petri dish, each with a growth surface area
of 0.95 mm2. The cell population detected was the
primitive hematopoietic stem cell or colony-forming
unit – granulocyte, erythroid, macrophage, megakaryo-
cyte (CFC-GEMM) stimulated with erythropoietin (EPO),
granulocyte-macrophage colony stimulating factor (GM-
CSF), thrombopoietin (TPO), stem cell factor (SCF), Flt-3
ligand and interleukins 3 and 6 (IL-3, IL-6). Cells were
cultured in a 37°C humidified incubator gassed with 5%
CO2 and 5% O2 [29]. Colonies were manually counted
using an inverted microscope (40 – 100× magnification,
Zeiss, U.S.A.) after 9–10 days of incubation to ensure that
the colonies do not grow together. This is a shorter incu-
bation period than normal for CFU cultures (14–16 days)
and is primarily due to a difference in methylcellulose cul-
ture reagent formulation and the smaller growth surface
area than for a 35 mm Petri dish.
ATP Bioluminescence proliferation assay (assay
performed in 96 plate)
Since the CFU assay cannot be used to directly measure
the proliferation of stem cells, a 96-well plate, ATP bio-
luminescence assay was employed (HALO, HemoGenix,
Colorado Springs, CO). This has been described in detail
elsewhere [19,20,30]. In essence, when cells are stimu-
lated to proliferate, their intracellular ATP concentra-
tions increases several fold above the basal iATP level.
The change in iATP concentrations directly correlates
with the metabolic activity (viability) of the cells and
their proliferation status. After cell culture, the cells are
lysed to release iATP, which reacts with a luciferin/lucif-
erase reagent to produce bioluminescence. This is de-
tected as light in a luminescence plate reader. The assay
does not incorporate methylcellulose and therefore is
not a clonal assay. Instead, cells are grown and expanded
in suspension that not only allows increased accuracy
and sensitivity, but more rapid assay completion. Al-
though the assay can be performed in just 5 days with
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well), a more optimal 7 day incubation time period using
lower cell concentrations (1,000, 2,000 and 4,000 cells/
well) was used in the majority of experiments described.
As shown, this extra 2-day incubation produces an ap-
proximate 2–3 fold increase in ATP concentrations and
therefore a concomitant increase in assay sensitivity.
Prior to measuring any samples, the ATP biolumines-
cence stem cell proliferation assay was calibrated using
ATP calibrators and standardized using an external ATP
standard curve. This allowed the non-standardized read-
out in relative luminescence units (RLU) to be interpo-
lated as standardized ATP concentrations (μM). The
ATP standard curve is a series of five ATP dilutions
(from 0.01 μM to 1 μM) that produces a straight-line
curve that can be fitted by linear regression analysis. The
slope of the line must lie within specific upper and lower
limits. The ATP calibrators are known ATP concentra-
tions that must lie on the ATP standard curve and also
produce values within specific upper and lower limits.
When these conditions have been met, not only has an
internal proficiency test been performed to ensure that
the assay is working correctly, but also allows results
from different experiments to be directly compared
without normalization. In addition, the inclusion of
these steps allowed the assay to be validated [31,32] ac-
cording to regulatory guidelines [33].
All studies of UCB cell proliferation measured two stem
cell populations. Since the ATP proliferation assays were
methylcellulose-free and therefore not clonal, the first
stem cell population was the equivalent to, and designated
as, CFC-GEMM, using exactly the same growth factor
cocktail as described for the CFU assay. The second was
the more primitive lympho-hematopoietic high prolifera-
tive potential – stem and progenitor cell (HPP-SP), which
included, interleukins 2 and 7 (Il-2, IL-7). For these stud-
ies, all growth factors and cytokines were obtained from
CellGenix (Freiburg, Germany) and EPO was obtained
from Cell Sciences (Canton, MA, USA). For both of the
stem cell populations, two parameters of cell proliferation
were measured simultaneously. The first was proliferation
ability or status. It determines the amount of cell prolifera-
tion at a specific cell dose and point in time. The second
parameter was proliferation potential, which is measured
by the slope of the cell dose response linear regression
[34]. The more primitive a stem cell population the
greater the slope of the cell dose response and therefore
the greater the proliferation potential of the stem cell.
Measuring stem cell proliferation potential is also the
basis for measuring stem cell potency [31,32,35-37].
Statistics
Based on historical UCB sample data [32,35], a power cal-
culation was used to determine a minimum sample sizeneeded for the present studies (Systat Software, Version
13.1, San Jose, CA). For a power of 0.9, a total of 11 sam-
ples were required to reject our “null hypothesis”. In fact,
a total of 63 individual cord blood segments obtained
from two different cord blood banks were tested. Studies
were initiated on 22 segment samples cultured for 5 days
at high cell concentrations. The remaining 41 segments
were tested at lower cell concentrations for 7 days. The
standardized ATP assay allowed all of the results to be
compared directly. In addition, several of the segments
were provided in duplicate allowing a comparison not
only between individual segments from the same lot
(unit), but also to determine if differences might be due to
methodological changes performed by the investigators.
To determine if methodology might be a contributing fac-
tor to differences observed between segments, a Bland-
Altman statistic was used. For the CFU assay, each data
point was performed in quadruplicate and results calcu-
lated as the mean ± standard deviation. For the ATP pro-
liferation assay, 8 replicates were performed for each data
point. All of the results from these assays are based on
raw data and are expressed as the mean ± standard devi-
ation (SD) or standard error of the mean (SEM), where
appropriate. In addition, the percent coefficients of vari-
ation (%CV) were also evaluated. To determine the slope
of the cell dose response, linear regression analysis was
performed given by parameter B in the equation Y =A +
Bx, where A is the intercept with the ×-axis. For linear re-
gression analysis, the slope and the correlation coefficient
(r) were calculated. The goodness of fit (R2) was omitted
since this can be calculated from the square root of the
correlation coefficient. For all results demonstrating cell
proliferation, the historical acceptance/rejection limit was
0.04 μM ATP± 15%. This is provided in all applicable
graphs. Cells exhibiting ATP values greater than 0.04 μM
are usually capable of sustaining proliferation. Cell exhi-
biting ATP values within or just below the acceptance/
rejection level will have limited proliferation capability,
while cells showing ATP values of 0.01 μM or less will
be metabolically dead and will not proliferate. Depend-
ing on whether a comparison was made between two
groups or multiple groups, a two-tailed t-test or two-
way analysis of variance (ANOVA) was performed, re-
spectively. This and all other statistical analyses, with
the exception of power analysis, used GraphPad Prism
software (version 6f for Mac).
Results
Cord blood component parameters before and after
fractionation
Table 1, shows the mean values of the basic cord blood
components from 56 untreated (TNC fraction) and
treated (MNC fraction) segments. Although cryopreser-
vation results in lysis and cell death of many cell
Table 1 Combined percent reduction of mature blood components between TNC and MNC fractions for 56 segment
samples
Segment cell composition TNC fraction (Mean ± St.Dev) MNC fraction (Mean ± St.Dev) Percent reduction (Mean ± St.Dev)
RBCs (× 1012/L) 0.74 ± 0.19 0.19 ± 0.09 74.32 ± 16.75
Hematocrit (%) 12.21 ± 0.034 1.52 ± 0.02 87.55 ± 20.45
Platelets (× 109/L) 258.84 ± 124.04 15.34 ± 14.79 94.07 ± 5.25
White blood cells (× 109/L) 20.04 ± 7.48 2.44 ± 3.00 87.82 ± 12.26
Granulocytes (× 109/L) 2.30 ± 1.22 0.11 ± 0.03 95.22 ± 1.28
Lymphocytes (× 109/L) 14.64 ± 5.51 1.72 ± 1.16 88.25 ± 10.34
Viability (%) 95.80 ± 1.13 99.76 ± 0.07 2.54
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main post-thaw. Preparation of a MNC fraction further
reduces these components and it would appear that a
significant proportion of the components that make up
the MNC fraction are removed or are lost from the
TNC fraction. It might be assumed that this reduction
also occurs for the stem cells. With a recovery of 30% or
less, density gradient centrifugation is one of the least ef-
ficient cell purification methods. Nevertheless, as shown
in the results below, the cell impurities in the post-thaw,
TNC fraction mask and impair the stem cells to such an
extent that it is difficult to accurately and reliably assess
their presence and functional potential.
The CFU differentiation assay and correlation with the
ATP proliferation assay
Two different investigators prepared their own TNC and
MNC fractions from two cord blood segments derived
from the same lot or unit. The CFU assay was per-
formed at 1,200, 2,500 and 5,000 cells/well to detect the
CFC-GEMM stem cell population. The total colony
counts were enumerated after 9–10 days of culture by
each person and shown in Figure 1A. Although the
number of colonies counted was different for each inves-
tigator, the correlation coefficients (r) for each cell dose
response were high, indicating a high enumeration preci-
sion. Furthermore, not only were fewer colonies counted
from the TNC fraction compared to the MNC fraction,
but the slopes of the cell dose response curves for the
TNC fraction were lower than those of the MNC frac-
tion. This implied that the presence of non-colony form-
ing cells in the TNC fraction was impairing the clonal
growth of the stem cells.
In parallel with the CFU assay, the same investigators
using the same cell preparations and dilutions also pre-
pared an ATP proliferation assay. The cells were cul-
tured for 7 days and the ATP concentrations measured
after the assay had been calibrated and standardized as
described in the Method section. Figure 1B shows how
the total colony counts from the CFU assay correlate
directly with ATP concentration values. Like the resultsfrom the CFU assay, not only were the correlation coef-
ficients of the cell dose response linear regressions high,
but the cord blood TNC fraction produced lower ATP
concentrations with a concomitant lower slope for the
linear regressions than the MNC fraction. Lower colony
counts combined with a decreased slope for the cell dose
response, indicated that the TNC fraction affects assay
sensitivity caused by other cell impurities. This implies
that the lower stem cell response from a TNC fraction
might not allow high-quality UCB units to be saved for
patient use.
In Table 2, the CFU and ATP values are calculated as
1 × 105 cells and total cells in the segment. For both the
number of colonies counted and the ATP concentration
measured, the MNC fraction produced higher values than
the TNC fraction, although the CFU total colonies for the
TNC fraction were not significantly different. In addition,
the %CVs for the TNC fraction was approx. 30%, while
those for the MNC fraction were less than 10%.
The effect of cell dose and incubation time on the cord
blood stem cell response
Figure 2 shows the combined results from 22 cord
blood segments each prepared as both a TNC and
MNC fraction and tested as 2,500, 5,000 and 7,500
cells/well with a 5 day incubation (Figure 2A) and 41
cord blood segments tested at 1,000, 2,000 and 4,000
cells/well with a 7 day incubation (Figure 2B). For all
cord blood segments, the proliferation potential for
both the HPP-SP and CFC-GEMM stem cell popula-
tions were measured.
The results demonstrate that low cell doses combined
with a longer incubation time of 7 days produce a more
sensitive assay than higher cell doses cultured for only
5 days. For both the TNC and MNC fractions, the HPP-
SP exhibits a steeper slope than that for CFC-GEMM,
indicating that the former has a greater proliferation po-
tential, is more primitive and therefore more potent than
the latter stem cell population. More important, how-
ever, is the observation that the TNC fraction produces
“stunted” proliferation for both stem cell populations
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Figure 1 Correlation between the CFU Differentiation and Proliferation Assays for TNC and MNC Cord Blood Fraction. A. The Difference in Total
CFU Colony Counts for CFC-GEMM Stem Cell Population Enumerated for TNC and MNC Fractions by Two Investigators (P1 and P2). Cell dose response
linear regressions. TNC, P1: Slope = 0.0095, r = 0.895. MNC, P1: Slope = 0.0230, r = 0.922. TNC, P2: Slope = 0.0062, r = 0.89. MNC, P2: 0.016, r = 0.91.
Probability of the linear regression slopes being equal?. TNC P1 vs MNC P1, P = 0.0009. TNC P2 vs MNC P2, P = 0.0008. TNC P1 vs TNC P2, P = 1.0. MNC
P1 vs MNC P2, P = 0.096. TNC P1 vs MNC P2, P = 0.03. TNC P2 vs MNC P1, P = 0.0001. Two-way ANOVA to determine differences between TNC vs
MNC and P1 vs P2. TNC P1 vs MNC P1, P = 0.0002. TNC P2 vs MNC P2, P = 0.02. TNC P1 vs TNC P2, P = 0.19. MNC P1 vs MNC P2, P = 0.0001. TNC
P1 vs MNC P2, P = 0.0001. TNC P2 vs MNC P1, P = 0.33. B. Correlation Between Total CFU Colony Counts for CFC-GEMM Enumerated on Day 10
and CFC-GEMM Proliferation Detected by ATP Bioluminescence on Day 7. Cell dose response linear regressions for 1,250, 2,500 and 5,000 cells/well.
TNC, P1: Slope = 0.0137, r = 0.99. MNC, P1: Slope = 0.017, r = 0.99. TNC, P2: Slope = 0.0086, r = 0.99. MNC, P2: Slope = 0.015, r = 0.99.
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is directly related to “masking” of the rare stem cell pop-
ulations by other cell impurities in TNC fraction.Table 3 shows the combined CVs for the TNC and
MNC for the cord blood segments analyzed at low cell
concentrations after 7 days of incubation. The results
Table 2 Calculation of total primitive hematopoietic stem
cell (CFC-GEMM) activity based on the number of
colonies and ATP concentrations at 2,500 cells
CFC-GEMM at
1 × 105 cells
Total CFC-GEMM
Colony number in TNC fraction 800 ± 242 37,840 ± 11,424
Colony number in MNC fraction 3,175 ± 300 49,085 ± 4,279
ATP (μM) in TNC fraction 8.8 ± 2.6 416 ± 125
ATP (μM)in MNC fraction 35.4 ± 3.3 673 ± 47
Calculation of total CFC-GEMM was performed as described by Page et al. [10]
and was based on a recovery of 29.03% after density gradient centrifugation.
This recovery was similar to that obtained by Basford et al. [30].
Statistics for CFU Assay.
TNC fraction vs MNC fraction: CFU/105, P = <0.0001; Total CFU, P = 0.15.
Statistics for ATP Assay.
TNC fraction vs MNC fraction: ATP/105, P = <0.0001; Total ATP, P = 0.024.
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the samples. The variance between the stem cell popula-
tions in the MNC fraction is between 30 and 50%, while
the variance for both stem cell populations within the
TNC fraction is not only less constant, but in some
cases, more than twice that of the respective MNC
population.
Comparison between segments from the same lot
Segments were analyzed in pairs from 12 different UCB
lots. This allowed the stem cell response from each seg-
ment to be directly compared with each other. Each seg-
ment from a pair was processed by different people
using the same methodology. Bland-Altman statistics
demonstrated that the results obtained were not due to
differences in methodology. Therefore, the differences
between the segment pairs were due to the different
composition of the cells between the two segments from
the same unit. Figure 3 shows the combined box and
whisker plots for 3-point cell dose response linear re-
gression curves for each stem cell population detected
in each of the two post-thaw, unseparted (TNC) and
separated (MNC) segments. The details of the box
and whisker plots are given in the legend. The asterisks
show which groups of data were significantly different
(P = < 0.05) from TNC, CFC-GEMM segment 1, accord-
ing to a two-way ANOVA.
The only groups that were statistically different within
the TNC set of samples were the HPP-SP stem cell popu-
lation in both segments 1 (P = 0.003) and 2 (P = 0.013).
The lack of statistical difference between segments 1
and 2 within the TNC set is due to the low ATP concen-
trations and the high variances produced by this set of
data. All the MNC data demonstrated greater ATP con-
centrations than the TNC data and therefore significant
differences were seen for both segments 1 and 2 at
the 2,000 and 4,000 cell/well levels for both stem cell
populations. Also noteworthy was the observation thatwhen linear regression curves were fitted to the TNC
data from segments 1 and 2 for each of the stem
cell populations, the results showed either no correl-
ation or a negative correlation, thereby indicating a dif-
ference between the segments of the same unit (data
not shown) [38].
The relationship between cord blood segment and unit
Usually, between two and four contiguous segments are
produced and cryopreserved with the UCB unit. One or
more of the segments are used primarily for HLA con-
firmatory testing, but if sufficient cells are available, via-
bility, CD34 and even a CFU assay may also be
performed. The object is to confirm that the cells in the
segment represent those in the unit and therefore should
provide some assurance that the unit can be released
and that the cells will perform as expected. Reports have
shown that the segment is representative of the sample
[39], but others have a shown a discrepancy with respect
to the position of the segment in relation to the unit
[40]. To test whether the segment is a true representa-
tion of the UCB unit, several units with attached seg-
ments were examined in parallel. After thawing, an
aliquot of the unseparated, TNC fraction was removed
from both the segment and the unit. A cell count, viabil-
ity, and a 3-point cell dose response for CFC-GEMM
determined by the CFU assay and CFC-GEMM and
HPP-SP measured using ATP bioluminescence. The
remaining cells from the segment were processed to a
MNC fraction. All of the remaining cells from the unit
were divided equally and also processed to a MNC frac-
tion, but by different investigators.
Table 4 shows the differential composition of the TNC
and MNC fractions for both the segment and the unit.
The same considerations described for Table 1 also
existed for both the segment and unit in that a consider-
able number of cells were removed or lost. Despite the
low efficiency of the method (which would be consider-
ably improved using automated methods), it remains
clear that the post-thaw, TNC fraction contributes to a
significant underestimate of the stem cell activity in both
the segment and the unit. Figure 4A shows a typical
CFU assay for CFC-GEMM and Figure 4B shows the
combined results in which CFC-GEMM and HPP-SP
stem cell populations (ATP assay) from TNC and MNC
fractions were compared between the segment and the
unit. The results can be summarized as follows. (1) Both
CFU and ATP bioluminescence exhibit the same pattern
of results with the TNC fractions showing a lower re-
sponse than the MNC fractions. (2) The results from up
to 9 separate MNC fractions from the unit demonstrated
a separate clustering of results for both the CFC-GEMM
and HPP-SP stem cell populations, with the latter gener-
ally showing a higher slope than the CFC-GEMM


























































































Figure 2 Optimization of Cell Dose and Incubation Time to Determine the Cord Blood Stem Cell Response for TNC and MNC Fractions.
A. Proliferation Potential of CFC-GEMM and HPP-SP Present in Either TNC or MNC Cultured at High Cell Concentrations (2,500, 5,000, 7,500 cells/
well) for 5 Days. Dotted lines represent the TNC fraction, while solid lines represent the MNC fraction. Cell dose response linear regression parameters
for N = 22. TNC, CFC-GEMM: Slope = 1.18 × 10-5, r = 0.99. TNC, HPP-SP: Slope = 1.84 × 10-5, r = 0.99. MNC, CFC-GEMM: Slope = 3.69 × 10-5, r = 0.99.
MNC, HPP-SP: Slope = 4.92 × 10-5, r = 1.0. Probability that the slopes of the linear regression curves are different. TNC CFC-GEMM vs TNC HPP-SP,
P = 0.1. MNC CFC-GEMM vs MNC HPP-SP, P = 0.007. TNC CFC-GEMM vs MNC CFC-GEMM, P = 0.02. TNC HPP-SP vs MNC HPP-SP, P = 0.05. Two-way
ANOVA between the different response curves shown on the graph as P values. B. Proliferation Potential of CFC-GEMM and HPP-SP Present in Either
TNC or MNC Cultured at Low Cell Concentrations (1,000, 2,000 and 4,000 cells/well) for 7 Days. Dotted lines represent the TNC fraction, while solid lines
represent the MNC fraction. Cell dose response linear regression parameters for N = 41. TNC, CFC-GEMM: Slope = 4.38 × 10-5, r = 1.0. TNC, HPP-SP:
Slope = 8.04 × 10-5, r = 0.99. MNC, CFC-GEMM: Slope = 0.00016, r = 1.0. TNC, HPP-SP: Slope = 0.00023, r = 1.0. Probability that the slopes of the linear
regression curves are different. TNC CFC-GEMM vs TNC HPP-SP, P = 0.34. MNC CFC-GEMM vs MNC HPP-SP, P = 0.0008. TNC CFC-GEMM vs MNC
CFC-GEMM, P = 0.03. TNC HPP-SP vs MNC HPP-SP, P = 0.02. Two-way ANOVA between the different response curves shown on the graph as P values.
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Table 3 Mean coefficients of variation for stem cell populations derived from TNC and MNC fractions tested at low cell
doses (1,000, 2,000 and 4,000 cells/well) for 7 days
Cell concentration / well TNC CFC-GEMM MNC CFC-GEMM TNC HPP-SP MNC HPP-SP
1,000 100.1% 55.0% 88.8% 55.3%
2,000 85.9% 37.3% 127.6% 51.8%
4,000 101.3% 47.2% 89.6% 47.6%
Patterson et al. Journal of Translational Medicine  (2015) 13:94 Page 9 of 16population (see (5) below). (3) Using two-way ANOVA,
there was no statistical difference between stem cell pop-
ulations derived from the segment or unit TNC fractions
(Figure 4B). This is because the ATP concentrations
were too low and the variances too high to allow differ-
ences to be distinguished. This might imply that the
“null hypothesis” is correct and that for TNC fractions,
the segment represents the unit. (4) ATP concentrations
from MNC fractions were 3–7 fold greater than those
from TNC fractions. Thus, the TNC segment and unit,
both provide stem cell response values that severely
underestimate the capability of the cells in the unit. Not
only was there a statistical difference between the TNC
and MNC fractions for both stem cell populations from
the segment and unit, but also between MNC-derived
stem cell populations from the segment and unit. This










































Figure 3 Comparison Between Paired UCB Segments. The results repre
lots. Segments were randomly allocated as Segment 1 and 2. For each seg
unseparated, TNC and separated, MNC fractions. The results are provided a
2,000 cells/well, light grey box; 4,000 cells/well, dark grey box) for a total of
and 75 percentiles. The horizontal line and “+” sign within the box represe
(error bars) represent the 5 and 95% confidence intervals. The asterisk (*) re
(P =< 0.05) of the respective cell dose compared to the CFC-GEMM, TNC, S
graph represent the acceptance/rejection levels ± 15% for cell proliferationinto account (Table 5). (5) In some cases, the cell dose
response slopes for both stem cell populations derived
from the MNC fraction for the segment and unit were
statistically parallel, indicating a very low number or lack
of primitive lympho-hematopoietic stem cells. This ob-
servation implies the absence of cells that could provide
long-term engraftment and reconstitution (data not
shown). (6) The response of the stem cells in the MNC
fraction of the unit provides a more realistic indication
of the unit capability. (7) It appeared that the further the
segment was from the unit bag, the greater the discrep-
ancy in the stem cell response between the segment and
the unit.
Table 5 shows the calculated colony number and ATP
concentrations for the two stem cell populations de-
tected in the TNC and MNC fractions of both the seg-
ments and unit. CFU colony counts based on 1 × 1052 Segment 1 Segment 2 Segment 1 Segment 2










sent the combined data from 12 segment pairs from different UCB
ment, two stem cell populations were measured from both the
s box and whisker plots for each cell dose (1,000 cells/well, clear box;
12 paired segments. The top and bottom of the box represent the 25
nt the median and mean of the results, respectively. The whiskers
presents results from a two-way ANOVA showing a statistical difference
egment 1 sample. The dotted horizontal lines at the bottom of the
measured by ATP bioluminescence.












RBCs (× 1012/L) 1.64 ± 0.5 0.5 ± 0.42 0.94 ± 0.3 0.7 ± 0.4
Hematocrit (%) 28.5 ± 9.2 9.0 ± 4.8 15.5 ± 1.0 8.9 ± 6.4
Platelets (× 109/L) 279.0 ± 67.9 35.8 ± 34.4 183 ± 16.3 46.3 ± 6.7
White blood cells (× 109/L) 20.6 ± 6.0 2.5 ± 2.7 12.1 ± 3.3 3.1 ± 0.3
Granulocytes (× 109/L) 12.6 ± 4.5 0.1 ± 0.14 1.0 ± 0.2 0.1 ± 0.05
Lymphocytes (× 109/L) 15.5 ± 1.8 2.4 ± 0.5 9.2 ± 2.6 2.8 ± 0.3
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segment and unit (P > 0.05) and MNC segment and unit
(P > 0.05). Based on the CFU output, this might imply
that the segment represented the unit. However, the cal-
culated total CFC-GEMM content for the MNC fraction
does not confirm this. When the proliferation ability of
the stem cells was examined based on 1 × 105 cells, the
TNC fractions in the segments and unit were also simi-
lar, but the values for the MNC fractions were signifi-
cantly different between the segment and unit for both
stem cell populations. These differences were also ob-
served when total UCB unit values were calculated.
These results illustrate the need for caution in assuming
that the segment is a true representation of the unit.
Comparison between umbilical cord blood samples from
two cord blood banks
The 41 sample segments tested at low cell doses for
7 days, were obtained from two cord blood banks (CBB),
12 from CBB1 and the remainder from CBB2. Table 6
shows the mean and SEM of the combined cell dose re-
sponse data for each of the stem cell populations deter-
mined from the TNC and MNC fractions for each cord
blood bank. It would appear that CCB1 produces sample
segments in which the overall stem cell proliferation
ability (determined at 4,000 cells/well), is greater than
CCB2. However, also shown are the percent CVs. These
values indicate that for both CBBs, the TNC fraction
produces lower values and higher variances compared to
the MNC fraction. Comparing the results between CBBs
using ANOVA produced differences in results for stem
cell populations detected only at the higher cell dose
levels. In addition, it was only at these high cell dose
levels that significant differences were seen between
TNC and MNC fractions.
The relationship between viability and ATP
bioluminescence
Table 1 showed similar viability values between TNC and
MNC fractions. Indeed, during the course of these studies,
it became clear that the percent viability, detected by7-AAD, did not correspond to the metabolic viability de-
tected when either the CFC-GEMM or HPP-SP were
stimulated. It is important to distinguish between these
two types of viability measurement. Dye exclusion viability
using 7-AAD and flow cytometry detects membrane in-
tegrity, whereas ATP (and other metabolic biochemical
markers such as MTT) require active mitochondria and
detect metabolic and cellular integrity and therefore pro-
vides a functional measure of viability. Figure 5 demon-
strates that the high dye exclusion viability obtained from
TNC fractions does not correspond to the low prolifera-
tion found with either stem cell population. Indeed, even
the viabilities obtained for the MNC fractions, which were
close to 100%, did not correlate with stem cell prolifera-
tion. These results indicate that using dye exclusion viabil-
ity as a means of predicting cell growth can produce high,
false positive values and therefore can significantly influ-
ence the interpretation of the results.
Discussion
The results presented in this communication demon-
strate that rare stem cell populations can be detected
and quantitatively measured in very small volumes of
UCB sample segments. The results also show that UCB
cell preparation purity and viability can have a signifi-
cant influence on detecting specific cell populations as
well as how they are measured. Compared to the MNC
fraction, the cell impurities in the TNC fraction are not
only responsible for producing high variability, but also
masking the presence of the rare stem cells populations.
This, in turn, significantly underestimates, both the qual-
ity and potency of the stem cells in the UCB segment
and unit. The TNC fraction is considered one of the
basic parameters upon which several important assump-
tions are made, including whether the unit will be stored
for transplantation purposes and uploaded to a cord
blood inventory, the quality of the unit, its release for
transplantation purposes and correlation with clinical
outcome [41]. The present results not only call into
question the use of pre-freeze testing to represent the
post-thaw unit, but many of the assumptions regarding


























































































No signficant difference between cell populations derived
from segment or unit
Figure 4 Stem Cell Response between Cord Blood Segment and Unit for TNC and MNC Fractions. A. An Example of CFU Results for the
CFC-GEMM Stem Cell Population from a Unit and Segment. Closed circles, dotted line; TNC segment: Slope = 0.001, r = 0.92. Closed triangles,
dotted and dashed line; TNC unit: Slope = 0.0017, r = 0.98. Closed squares, dashed lines; MNC segment: Slope = 0.018, r = 0.99. Inverted triangles,
solid line; MNC unit: Slope = 0.035, r = 1.0. B. Difference in Cell Purity and Stem Cell Population Response for UCB Segments and Units. Results
are for ATP bioluminescence stem cell proliferation assays at 4,000 cells/well and statistically comparing different parameters using a two-way
ANOVA. The horizontal dotted lines at the bottom of the graph indicate the acceptance/rejection limits of the assay ± 15%. None of the values
from TNC fractions were significantly different from each other. All ATP concentrations obtained from MNC fractions were highly significant from
the TNC values (from P = 0.01 for CFC-GEMM from the MNC segment to P = 0.0002 for HPP-SP from the MNC unit.). The statistical differences
(P values) between stem cell populations and segment and unit for MNC fractions are shown on the graph.
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Table 5 Calculation of total stem cell activity between the umbilical cord blood segment and unit based on the
number of colonies and ATP concentrations at 2,000 cells/well
CFU assay
CFC-GEMM at 1 × 105 cells HPP-SP at 1 × 105 cells Total CFC-GEMM Total HPP-SP
Colonies – TNC Segment 475 ± 96 ND 6,835 ± 1,374 ND
Colonies-MNC Segment 2,275 ± 433 ND 13,533 ± 2,005 ND
Colonies – TNC Unit 487.5 ± 165 ND 8,141 ± 2,759 ND
Colonies – MNC Unit 2,400 ± 248 ND 23,624 ± 1,617 ND
ATP Bioluminescence Proliferation Assay
CFC-GEMM at 1 × 105 cells HPP-SP at 1 × 105 cells Total CFC-GEMM in the Unit Total HPP-SP in the Unit
ATP (μM) - TNC Segment 22.0 ± 15.1 24.1 ± 20.0 317 ± 217 347 ± 288
ATP (μM) – MNC Segment 58.5 ± 6.5 73.8 ± 2.4 494 ± 44 597 ± 16
ATP (μM) – TNC Unit 29.0 ± 8.6 33.9 ± 11.1 8,732 ± 2,572 10,180 ± 3,335
ATP (μM) – MNC Unit 88.2 ± 11.9 107.2 ± 11.5 13,679 ± 1,440 17,991 ± 1,396
ND = not done.
Statistics for CFU assay.
TNC segment vs MNC segment: Colonies/105, P = 0.76; Total colonies, P = 0.17.
MNC unit vs MNC unit: Colonies/105, P = 0.57; Total colonies, P = 0.013.
Statistics for ATP assay.
TNC segment vs MNC segment for CFC-GEMM: ATP/105, P = <0.0001; Total ATP, P = 0.024. For HPP-SP: ATP/105, P = <0.0001; Total ATP, P = 0.0032.
TNC unit vs MNC unit for CFC-GEMM: ATP/105, P = <0.0001; Total ATP, P = 0.01. For HPP-SP, ATP/105, P = <0.0001; Total ATP, P = 0.032.
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determined prior to transplantation.
The ATP bioluminescence signal detection system is the
most sensitive, non-radioactive readout available for cell
viability and function [42]. Previous studies had demon-
strated the correlation between CFU colony counts and
the measurement of iATP as a biochemical marker for
hematopoietic cell proliferation [43]. The present results
again demonstrate this correlation for UCB stem cells not
only in sample segments, but also in the whole unit. This
verification of one assay against the other substantiated
the use of the ATP bioluminescence, CFU-alternative
assay to perform this study. That the ATP biolumines-
cence stem cell proliferation assay is calibrated and stan-
dardized, thereby providing an internal proficiency testTable 6 Comparison between umbilical cord blood samples fr
Cord Blood Bank 1 (N = 12)
Cell concentration Cell population TNC (mean ± SEM %CV) MNC (m
1,000 CFC-GEMM 0.09 ± 0.03, 91.9% 0.238 ± 0
HPP-SP 0.099 ± 0.03, 99.7% 0.323 ± 0
2,000 CFC-GEMM (+) 0.165 ± 0.04, 74.2% 0.544 ± 0
HPP-SP (*) 0.21 ± 0.06, 79.6% 0.723 ± 0
4,000 CFC-GEMM (*) 0.284 ± 0.08, 87.4% 0.887 ± 0
HPP-SP (*) 0.396 ± 0.1, 73.0% 1.352 ± 0
Samples from CBB 1 used Sepax technology.
Samples from CBB 2 used AXP technology.
(+) represents 2,000 cells/well between MNC from CBB1 vs CBB2, P = 0.05.
(*) represents MNC from CBB1 vs CBB2, P < 0.001.
[1] represents TNC vs MNC from CBB1, P = 0.05.
[2] represents TNC vs MNC from CBB1, P < 0.001.
[3] represents TNC vs MNC from CBB2, P = 0.05.
[4] represents TNC vs MNC from CBB2, P < 0.001.every time samples are processed, and has been validated
according to regulatory guidelines [33], lends further cred-
ibility to the results.
Cell viability and nucleated cell counts are two of the
most basic laboratory parameters required to perform
most cell-based assays. Dye exclusion methods such as
trypan blue, propidium iodide, acridine orange and
7-AAD are regularly used to measure cell viability for
many applications. The use of 7-AAD is usually combined
with the measurement of CD34 by flow cytometry to de-
termine the number of viable CD34+ cells in the UCB seg-
ment and/or unit [44,45]. It has always been assumed that
dye exclusion viability provides a rapid and reliable meas-
ure of live/dead cells in the suspension. The possibility
that a viability measurement may produce false positiveom two cord blood banks
Cord Blood Bank 2 (N = 29)
ean ± SEM %CV) TNC (mean ± SEM %CV) MNC (mean ± SEM %CV)
.06, 64.5% 0.057 ± 0.01 91.7% 0.122 ± 0.01, 60.6%
.06, 56.5% 0.06 ± 0.01, 90.3% 0.146 ± 0.02, 58.7%
.1, 57.6% [1] 0.085 ± 0.01, 86.3% 0.25 ± 0.02, 46.1% [3]
.13, 56.2% [2] 0.126 ± 0.03, 111.0% 0.308 ± 0.03, 79.7% [3]
.16, 58.2% [2] 0.177 ± 0.03, 81.9% 0.499 ± 0.05, 49.0% [4]
.2, 47.4% [2] 0.293 ± 0.05, 87.8% 0.704 ± 0.06, 45.9% [4]





















































Acceptance / Rejection ± 15% 
Figure 5 Dye Exclusion Viability Versus Metabolic Viability and Stem Cell Proliferation for TNC and MNC Fractions. Percent viability,
detected by 7-AAD and flow cytometry, is shown on the left Y-axis, while mean ATP concentration (μM) / well is given on the right Y-axis. The
results show individual measurement as symbols. The mean (dark horizontal line) ± 95% confidence intervals are provided as error bars. Values
outside the top and bottom bars indicate outliers.
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repercussions. These include the decision to permanently
store a UCB unit, add it to a cord blood inventory, and
use the unit for transplantation purposes.
The TNC count has been used in hematopoietic cell
transplantation for decades. By definition, the TNC frac-
tion contains virtually all nucleated cells, including gran-
ulocytes, as well as varying concentrations of platelets,
red blood cells and other cell types. Many of these are
lysed or killed during the cryopreservation process. It is
not known whether stem cells undergo the same fate.
Nevertheless, the post-freeze TNC fraction still contains
high levels of cell impurities. These impurities do not
contribute to the engraftment process and, as demon-
strated in both the segment and unit, actually hinder the
detection of the stem cells responsible for engraftment
by diluting and “masking” their presence. This effect has
also been observed using the CFU assay [24]. Although
density gradient centrifugation is a simple and rapid
purification step from the TNC to MNC fraction and
was perfectly suitable to test the hypothesis proposed for
these studies, it is certainly not optimal for the rapid and
cost-effective processing of large numbers of UCB units.Automated, “closed” systems have been available to fur-
ther purify the cells in UCB units for some time [22,24],
but are rarely used, since cord blood banks normally
perform plasma and red blood cell reduction. It would
appear that storing UCB units as MNC fractions instead
of TNC fractions would provide more accurate and reli-
able results that would be more relevant to the trans-
plant physician, since at the very least, it affects both the
“quality” and potency of the UCB unit.
What constitutes a high-quality, and high potency
UCB unit, is still a matter of debate [46-48]. The non-
binding recommendations of the FDA [49] provide
values for the minimum TNC, viability and viable CD34
+ content as measures of purity and potency. For pro-
cessing, a UCB unit usually requires a TNC count of at
least 1 × 109 cells [50], with UCB units containing
greater than 1.79 × 109 TNC being preferred by trans-
plantation centers [26,51]. As demonstrated here, in-
creased cell dose correlates with increased ability to
detect and measure stem cell proliferation in the unit.
Therefore, the higher the TNC count, the greater the
proportion of stem cells in the unit and the higher the
probability of engraftment. This is because engraftment
Patterson et al. Journal of Translational Medicine  (2015) 13:94 Page 14 of 16is dependent upon the ability of the stem cells to prolif-
erate. If stem cell proliferation cannot be adequately
measured because impurities in the TNC fraction mask,
impair and underestimate their functionality, then the
quality of the UCB unit cannot be accurately and reliably
determined. By definition, the CFU-GEMM stem cell
population is characterized by the presence of granulo-
cytes and macrophages, erythroid cells and megakaryo-
cytes within a single colony. The identification of these
cell types by flow cytometry after stimulation of the
CFC-GEMM population in an ATP bioluminescence
assay was demonstrated previously [31]. However, most
methylcellulose formulations do not contain TPO re-
quired to potentiate stem cells and stimulate megakaryo-
poiesis. As a result, the population actually detected by
this reagent is more mature and therefore correlates to a
greater degree with CD34 and GM-CFC [46], than that
detected in the present studies. For normal UCB testing,
the CFU assay is used primarily to determine the pres-
ence of granulocyte-macrophage (GM) progenitor cells
as a predictor of granulocyte neutrophil production and
an indicator of time to neutrophil engraftment [10].
Since this is part of the early reconstitution process and
downstream from stem cell engraftment, detection of
GM-progenitor cell growth neither predicts nor deter-
mines the potential of the stem cells for engraftment
[50]. Even though determination of CD34 membrane ex-
pression is considered a “stem cell marker”, it is far from
specific [24], and provides no information on stem cell
functionality. The CD34 marker was not determined in
these studies because (a), it would have depleted cell
numbers for measuring cell proliferation, and (b), previ-
ous studies had shown that CD34 did not correlate with
ATP, since it is not a stem cell marker [32,35]. Taken to-
gether, it is necessary to seriously question the notion
that a UCB unit can be of high-quality and potency
when (a) the sample being tested is impure, and (b), that
the presence and functional properties of stem cells in
the product are not detected and measured to predict
engraftment potential.
Throughout these studies, a minimum 3-point cell dose
response was performed for all segments and units tested.
This allowed two parameters of stem cell proliferation to
be determined simultaneously. The first was the ability of
the stem cells to proliferate at a specific cell dose, and at
the time the sample was thawed. This parameter is prolif-
eration ability or status and is equivalent to stem cell “qual-
ity”. The second is proliferation potential, a key property of
stem cell primitiveness, and determined from the slope of
the stem cell dose response linear regression [34]. The
steeper the slope of the cell dose response, the more primi-
tive the stem cell population. As shown, the HPP-SP is
more primitive than the CFC-GEMM stem cell population.
However, proliferation potential correlates with severalother parameters. These include stem cell self-renewal cap-
acity and engraftment potential. These parameters are, in
turn, directly related to the potency of the stem cell popu-
lation; the more primitive a stem cell population, the
greater its proliferation potential and potency and, there-
fore, its engraftment potential. It has been shown previ-
ously that proliferation potential is a requirement for
measuring the potency of the “active” stem cell compo-
nents [31,32,35-37]. The present results clearly demon-
strate that measuring UCB stem cell proliferation is also a
requirement if accurate and reliable information is to be
accrued and used in the cord blood inventories.
The TNC count, viability, viable CD34+ count and the
total number of colonies or number of GM colonies
have been used for decades to characterize UCB samples
and equate the results to the unit. This was the reason
for hypothesizing that using the TNC fraction from UCB
segments and units did not have to be further purified
in order to accurately, reliably and reproducibly measure
the stem cells. The data presented above clearly reject
this hypothesis. Cord blood segments and units that
contain varying degrees of cell impurities cannot be used
to determine UCB stem cell quality or potency. It might
be argued that since hematopoietic stem cell transplant-
ation has been a routine procedure for decades using es-
sentially the same tests and assays, there is no reason to
characterize and measure the stem cells prior to infusion
into the patient. However, it is now obvious that several
basic assumptions upon which UCB transplantation have
been based, have now been called into question. Umbil-
ical cord blood transplantation continues to deal with
long engraftment times (usually 20–25 days) [8-10], and
a high rate of graft failure (20-24%) [8,10,52], both of
which are detrimental to the patient. Umbilical cord
blood is being used for numerous clinical applications
and virtually all use the same basic tests and assays and
therefore the same basic assumptions. As argued by
other authors [27,28], improvements can and should be
made. The present data clearly substantiates those argu-
ments, but also provides simple and substantive methods
for improvement that might help reduce engraftment
times, graft failure, and ultimately benefit the patient.
Conclusions
According to the NMDP [53], more than 25,000 cord
blood unit stem cell transplants have been performed
worldwide. All have been characterized using TNC, via-
bility, viable CD34 content and the CFU assay, but virtu-
ally none have been analyzed to ensure that the stem
cells responsible for engraftment exhibit high functional
quality and potency. Using a highly sensitive and stan-
dardized ATP bioluminescence stem cell proliferation
assay, it is shown that the TNC fraction, upon which
many of the decisions are made, from cord blood storage
Patterson et al. Journal of Translational Medicine  (2015) 13:94 Page 15 of 16to release of a unit for transplantation purposes, not
only dilute and mask the stem cells responsible for en-
graftment, but can underestimate the quality and po-
tency of the UCB unit. The results call into question
many of the premises that are being used in cord blood
banking and processing. These include differences be-
tween individual cord blood sample segments prepared
at the time the unit is processed and used for confirma-
tory testing, assuming the segment is a true representa-
tion of the cord blood unit and high false positive
viability values that do not correlate with the metabolic
viability and functionality of the stem cells in the seg-
ment or unit. The results demonstrate that the more
purified MNC fraction will provide more precise and ac-
curate measurements of stem cell properties that can be
used to better define the quality and potency of the cord
blood unit prior to use. Indeed, the results imply that
cord blood units should be stored as MNC rather than
TNC preparations. In addition, although testing must be
performed on the pre-freeze unit to determine stem cell
suitability for storage and later use, specific stem cell
quality and potency determinations should be per-
formed, and the information uploaded to cord blood
inventories, on samples of cells shortly after cryopreser-
vation. This would provide more relevant details on the
stem cell status that better represent the unit when it
is eventually selected by a transplantation center to treat
a patient.
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